Paragon acquired by NJ-based Catalent for $1.2 billion

Baltimore biotech firm Paragon Bioservices has been acquired by the New Jersey-based drug manufacturer Catalent, Inc. for $1.2 billion, Paragon announced Monday. Paragon, which specializes in biologics contract development and manufacturing, especially in gene therapy using viral vector manufacturing, employs about 380 people in Maryland and just opened a new manufacturing facility in Anne Arundel County ...

To purchase a reprint of this article, contact reprints@thedailyrecord.com.

Leave a Reply

Your email address will not be published. Required fields are marked *